Literature DB >> 11177669

Are all beta-blockers the same for chronic heart failure?

S S Gottlieb1.   

Abstract

beta-Adrenergic receptor blockade has been conclusively proven to increase survival and morbidity in patients with heart failure. Hospitalization rate decreases and patients feel better after receiving beta-blockers. Furthermore, this benefit is observed in a wide range of patients. The beta-blockers bisoprolol, metoprolol, and carvedilol have been extensively evaluated in heart failure patients. These drugs all show marked benefit. Bucindolol, an investigational beta-blocker, showed only mild improvement in survival in patients with heart failure. The beta-blockers differ regarding beta-selectivity, vasodilation properties, and perhaps other ancillary properties. At present, the importance and consequences of these differences are unknown.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11177669     DOI： 10.1007/s11886-001-0038-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  33 in total

1.  Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials.

Authors:  S Bonet; A Agustí; J M Arnau; X Vidal; E Diogène; E Galve; J R Laporte
Journal:  Arch Intern Med       Date:  2000-03-13

2.  Increased oxidative stress in patients with congestive heart failure.

Authors:  M Keith; A Geranmayegan; M J Sole; R Kurian; A Robinson; A S Omran; K N Jeejeebhoy
Journal:  J Am Coll Cardiol       Date:  1998-05       Impact factor: 24.094

3.  Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials.

Authors:  P Lechat; M Packer; S Chalon; M Cucherat; T Arab; J P Boissel
Journal:  Circulation       Date:  1998-09-22       Impact factor: 29.690

4.  Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

5.  Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.

Authors:  G Johnsson; N Svedmyr; G Thiringer
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

6.  Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.

Authors:  J E Sanderson; S K Chan; G Yip; L Y Yeung; K W Chan; K Raymond; K S Woo
Journal:  J Am Coll Cardiol       Date:  1999-11-01       Impact factor: 24.094

7.  beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling.

Authors:  S D Prabhu; B Chandrasekar; D R Murray; G L Freeman
Journal:  Circulation       Date:  2000-05-02       Impact factor: 29.690

8.  Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.

Authors:  M Metra; R Giubbini; S Nodari; E Boldi; M G Modena; L Dei Cas
Journal:  Circulation       Date:  2000-08-01       Impact factor: 29.690

9.  Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.

Authors: 
Journal:  Circulation       Date:  1995-07-15       Impact factor: 29.690

10.  Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.

Authors:  G Cintron; G Johnson; G Francis; F Cobb; J N Cohn
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690
View more
  2 in total

Review 1.  Purinergic signalling in the kidney in health and disease.

Authors:  Geoffrey Burnstock; Louise C Evans; Matthew A Bailey
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 2.  Heart rate during exercise: mechanisms, behavior, and therapeutic and prognostic implications in heart failure patients with reduced ejection fraction.

Authors:  Stefania Paolillo; Piergiuseppe Agostoni; Fabiana De Martino; Francesca Ferrazzano; Fabio Marsico; Paola Gargiulo; Elisabetta Pirozzi; Caterina Marciano; Santo Dellegrottaglie; Pasquale Perrone Filardi
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.